Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
Want to see XERS full AI Analyst Report?
Top Page
Xeris Pharmaceuticals
(NASDAQ:XERS)
Select Model
Select Model
Rating:66Neutral
Price Target:
$8.50
▲(33.44% Upside)
Action:Reiterated
Date:06/12/26
The score is driven primarily by the financial turnaround (positive earnings and strong free cash flow) and a supportive earnings update (raised revenue guidance and improving margins). These positives are offset by a still-fragile capital structure with thin equity and a demanding valuation (P/E ~95), while technicals are moderately favorable but not fully back to a long-term uptrend (still below the 200-day average).
Positive Factors
Cash Generation
Sustained positive operating and free cash flow is a durable improvement vs prior multi-year cash burn. Strong cash conversion reduces reliance on external financing, funds commercial and R&D investments, and provides a buffer to execute growth plans over the next several quarters.
Negative Factors
Fragile Equity / Leverage
Thin shareholder equity and a high debt-to-equity ratio leave limited balance-sheet cushion. Any setback in revenue or margins could rapidly erode solvency metrics or force dilutive financing, making capital structure a persistent vulnerability over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Sustained positive operating and free cash flow is a durable improvement vs prior multi-year cash burn. Strong cash conversion reduces reliance on external financing, funds commercial and R&D investments, and provides a buffer to execute growth plans over the next several quarters.
Read all positive factors
Xeris Pharmaceuticals (XERS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.33B
Dividend YieldN/A
Average Volume (3M)1.80M
Price to Earnings (P/E)108.6
Beta (1Y)1.29
Revenue Growth41.47%
EPS GrowthN/A
CountryUS
Employees394
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.07
Shares Outstanding172,642,060
10 Day Avg. Volume1,804,502
30 Day Avg. Volume1,797,482
Financial Highlights & Ratios
PEG Ratio-22.22
Price to Book (P/B)92.00
Price to Sales (P/S)4.32
P/FCF Ratio45.09
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.55
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda24.21
Forecast
1Y Price Target
$12.33Price Target Upside93.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.13
Revenue Forecast (FY)$385.85M
Xeris Pharmaceuticals Business Overview & Revenue Model
Company Description
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current por...
How the Company Makes Money
Xeris primarily makes money by commercializing prescription pharmaceutical products and recording product (net) revenue from sales to wholesalers, specialty pharmacies, and other customers, with revenue recognized net of typical industry deduction...
Xeris Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Positive
The call emphasized strong execution: substantial top-line growth (38% total revenue, 43% net product revenue), a near-doubling of Recorlev revenue (95% YoY), improved margins and profitability, and on-track pipeline progress with XP-8121 Phase III planned. Near-term headwinds were limited mainly to Gvoke (flat revenue) due to Medicare resets and increased near-term operating spend tied to deliberate commercial and R&D investments. Overall, positives (robust revenue growth, margin expansion, profitability, guidance raise and pipeline advancement) outweigh the operational and timing headwinds.Positive Updates
Strong Top-Line Growth
Total revenue of $83.1M in Q1'26, up 38% year-over-year; net product revenue of $82.5M, up 43% YoY, driven by Recorlev momentum.
Negative Updates
Gvoke Headwinds and Flat Revenue
Gvoke net revenue of $20.8M was flat YoY and slightly below internal expectations due to Medicare policy/plan changes (higher deductibles/out-of-pocket costs) that reduced prescription fills and total prescription volume in Q1.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total revenue of $83.1M in Q1'26, up 38% year-over-year; net product revenue of $82.5M, up 43% YoY, driven by Recorlev momentum.
Read all positive updates
Company Guidance
Xeris raised its 2026 revenue guidance to $380–$390 million (up from $375–$390M), implying more than 30% growth, driven by a strong Q1 that produced $83.1M total revenue (38% YoY), $82.5M net product revenue (43% YoY) including Recorlev $49.8M (95% YoY), Gvoke $20.8M (flat) and Keveyis $11.9M (4%); Q1 gross margin was 87% (+2%). Management expects R&D to increase by roughly $25M year‑over‑year (to fund XP‑8121 Phase III later this year) and SG&A to rise about $45M (reflecting the full‑year cost of a commercial expansion that now includes ~80 reps and ~12,000 targets), and reiterated a commitment to deliver positive adjusted EBITDA for 2026 that grows in absolute dollars versus 2025, with incremental benefit from the Recorlev expansion expected to materialize in the second half.Xeris Pharmaceuticals Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
46
Neutral
Cash Flow
81
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 314.85M | 291.85M | 203.07M | 163.91M | 110.25M | 49.59M |
| Gross Profit | 256.88M | 238.43M | 166.24M | 135.27M | 87.61M | 36.27M |
| EBITDA | 46.13M | 12.71M | -13.99M | -23.73M | -69.31M | -113.67M |
| Net Income | 12.01M | 554.00K | -54.84M | -62.26M | -94.66M | -122.72M |
Balance Sheet | ||||||
| Total Assets | 392.01M | 383.53M | 323.06M | 322.60M | 344.52M | 304.36M |
| Cash, Cash Equivalents and Short-Term Investments | 111.75M | 111.04M | 71.62M | 72.45M | 121.97M | 102.43M |
| Total Debt | 37.33M | 37.76M | 271.45M | 229.19M | 198.06M | 88.07M |
| Total Liabilities | 379.00M | 369.84M | 352.68M | 329.38M | 299.33M | 209.13M |
| Stockholders Equity | 13.01M | 13.69M | -29.61M | -6.78M | 45.19M | 95.23M |
Cash Flow | ||||||
| Free Cash Flow | 47.23M | 27.93M | -37.85M | -49.29M | -103.42M | -103.42M |
| Operating Cash Flow | 48.53M | 28.63M | -36.98M | -47.02M | -102.89M | -102.89M |
| Investing Cash Flow | -1.01M | -696.00K | 4.88M | -6.00M | 34.46M | 34.46M |
| Financing Cash Flow | 5.69M | 11.39M | 36.17M | -1.61M | 127.47M | 27.25M |
Xeris Pharmaceuticals Technical Analysis
Positive
6.37
Price Trends
6.40
Positive
6.28
Positive
7.03
Positive
Market Momentum
0.32
Negative
77.13
Negative
85.92
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XERS, the sentiment is Positive. The current price of 6.37 is below the 20-day moving average (MA) of 6.69, below the 50-day MA of 6.40, and below the 200-day MA of 7.03, indicating a bullish trend. The MACD of 0.32 indicates Negative momentum. The RSI at 77.13 is Negative, neither overbought nor oversold. The STOCH value of 85.92 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XERS.
Xeris Pharmaceuticals Risk Analysis
Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Xeris Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $1.33B | 108.62 | 735.00% | ― | 41.47% | ― | |
56 Neutral | $3.06B | ― | -68.97% | ― | 67.38% | 24.05% | |
52 Neutral | $1.79B | ― | -24.79% | ― | ― | -18.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.78B | -17.64 | -37.79% | ― | -12.98% | 8.99% | |
45 Neutral | $1.93B | ― | -48.84% | ― | -83.20% | -439.48% | |
44 Neutral | $1.89B | -7.61 | -256.66% | ― | 397.28% | 27.68% |
* Healthcare Sector Average
XERS
Xeris Pharmaceuticals
7.69
3.02
64.67%
SNDX
Syndax Pharmaceuticals
21.31
11.94
127.55%
ZYME
Zymeworks
24.15
11.60
92.43%
RCUS
Arcus Biosciences
31.00
22.86
280.84%
STOK
Stoke Therapeutics
32.00
20.65
181.94%
RAPP
Rapport Therapeutics, Inc.
40.06
28.69
252.33%
Xeris Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Xeris Biopharma Announces Debt Reduction via Note Exchanges
Positive
Jun 11, 2026
On June 10, 2026, Xeris Biopharma Holdings, Inc. entered into privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028, aiming to retire approximately $23 million in principal through a mix of ca...
Executive/Board ChangesShareholder Meetings
Xeris Biopharma Shareholders Elect Directors and Ratify Auditor
Neutral
Jun 5, 2026
On June 4, 2026, Xeris Biopharma Holdings, Inc. held its 2026 Annual Meeting of Stockholders, with 128,268,073 of 172,625,762 eligible shares represented, establishing a quorum. Shareholders elected two Class II directors, Dawn Halkuff and John Jo...
Business Operations and StrategyExecutive/Board Changes
Xeris Biopharma Announces Board Transition as Director Retires
Neutral
Apr 21, 2026
On April 20, 2026, Xeris Biopharma Holdings, Inc. announced that Dr. Jeffrey Sherman, a director since 2021 and member of both the Compensation Committee and the Nominating and Corporate Governance Committee, notified the company of his decision t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.